JP2013500986A5 - - Google Patents

Download PDF

Info

Publication number
JP2013500986A5
JP2013500986A5 JP2012523043A JP2012523043A JP2013500986A5 JP 2013500986 A5 JP2013500986 A5 JP 2013500986A5 JP 2012523043 A JP2012523043 A JP 2012523043A JP 2012523043 A JP2012523043 A JP 2012523043A JP 2013500986 A5 JP2013500986 A5 JP 2013500986A5
Authority
JP
Japan
Prior art keywords
compound according
group
compound
deleted
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012523043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500986A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/043719 external-priority patent/WO2011014661A2/en
Publication of JP2013500986A publication Critical patent/JP2013500986A/ja
Publication of JP2013500986A5 publication Critical patent/JP2013500986A5/ja
Pending legal-status Critical Current

Links

JP2012523043A 2009-07-29 2010-07-29 肝臓ｘ受容体アゴニスト Pending JP2013500986A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22938609P 2009-07-29 2009-07-29
US61/229,386 2009-07-29
PCT/US2010/043719 WO2011014661A2 (en) 2009-07-29 2010-07-29 Liver x receptor agonists

Publications (2)

Publication Number Publication Date
JP2013500986A JP2013500986A (ja) 2013-01-10
JP2013500986A5 true JP2013500986A5 (enExample) 2013-08-15

Family

ID=43529941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012523043A Pending JP2013500986A (ja) 2009-07-29 2010-07-29 肝臓ｘ受容体アゴニスト

Country Status (6)

Country Link
US (1) US8829213B2 (enExample)
EP (1) EP2459581A4 (enExample)
JP (1) JP2013500986A (enExample)
CN (1) CN102482315A (enExample)
CA (1) CA2769203A1 (enExample)
WO (1) WO2011014661A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI2753632T3 (fi) 2011-09-08 2023-08-02 Sage Therapeutics Inc Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä
CN103360456B (zh) * 2012-04-04 2015-07-29 浙江大学 三萜类化合物及制备和应用
CN103360453B (zh) * 2012-04-04 2015-10-07 浙江大学 四环三萜类化合物的制备和抗衰老应用
EP2759295A1 (en) 2013-01-29 2014-07-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Foam cell specific Liver X Receptor (LXR) alpha agonist, SIRT1 inhibitors as well as p300 inhibitors as pharmaceutically active agents
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
CN104072564B (zh) * 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
JP6320861B2 (ja) * 2013-10-16 2018-05-09 株式会社ファンケル コレステロール吸収阻害剤
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
EA033445B1 (ru) 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
EP3221331B1 (en) 2014-11-19 2019-09-18 Nzp Uk Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
EP3221333B1 (en) 2014-11-19 2019-07-24 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
JP6698085B2 (ja) 2014-11-19 2020-05-27 エヌゼットピー ユーケー リミテッド ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−６，７−ジオン−ステロイド
MX390271B (es) 2015-07-06 2025-03-20 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos
MA42409A (fr) 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
FI3828194T3 (fi) 2015-07-06 2025-07-17 Sage Therapeutics Inc Oxysteroleita ja menetelmiä niiden käyttämiseksi
US20190365784A1 (en) * 2015-12-30 2019-12-05 Raúl Enrique MASSONE Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators
US11648220B2 (en) 2016-01-11 2023-05-16 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN106188205B (zh) * 2016-05-06 2017-08-25 深圳以诺生物制药有限公司 一种罗汉果醇衍生物单体及其组合物的用途
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
IT201600068742A1 (it) * 2016-07-01 2018-01-01 Bar Pharmaceuticals Soc A Responsabilita Limitata Derivati dell'acido iodesossicolico e loro uso
LT3481846T (lt) 2016-07-07 2021-08-25 Sage Therapeutics, Inc. 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
JP7149266B2 (ja) 2016-09-30 2022-10-06 セージ セラピューティクス， インコーポレイテッド Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法
IL293231B2 (en) 2016-10-18 2025-10-01 Sage Therapeutics Inc Oxysterols and methods of use thereof
MA46566A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
EP3890745B1 (en) 2018-12-04 2025-11-19 President and Fellows of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
EP3893887A4 (en) * 2018-12-13 2023-01-04 Eyenos, Inc. LXR AGONIST IN TOPICAL OPHTHALMIC FORMULATION FOR THE TREATMENT OF DRY EYE
EP3965748A4 (en) 2019-05-10 2023-02-01 President and Fellows of Harvard College SMALL MOLECULE MODULATORS OF GUEST BACTERIAL BILE ACID METABOLISM
EP4073025B1 (en) 2019-12-13 2024-03-27 Inspirna, Inc. Metal salts and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698853A (en) * 1951-08-11 1955-01-04 Monsanto Chemicals Oxidation of steroids
FR1482102A (fr) * 1966-03-31 1967-05-26 Centre Nat Rech Scient Nouveaux dérivés de stéroïdes et procédé de préparation
US3784598A (en) * 1972-01-20 1974-01-08 Ciba Geigy Corp Process for the conversion of a 3-hydroxy-5,6-oxido group of a steroid into a delta4-3-oxo group
JPS4976857A (enExample) 1972-12-06 1974-07-24
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
US3887545A (en) * 1973-11-12 1975-06-03 Hoffmann La Roche Synthesis of 1{60 -hydroxylated cholesterol derivatives
US4006172A (en) * 1976-04-26 1977-02-01 The Upjohn Company Process for 7-keto-Δ5 -steroids
US4125544A (en) * 1977-06-09 1978-11-14 G. D. Searle 20/22/23/24-Oxa-7-oxocholesterols and esters thereof
US4193930A (en) * 1977-08-29 1980-03-18 G. D. Searle & Co. 25-Alkyl-3β-hydroxycholest-5-en-7-ones and esters thereof
DE2837414A1 (de) 1977-08-29 1979-03-08 Searle & Co 25-alkylcholesterin-derivate
JPS563000A (en) * 1979-06-20 1981-01-13 Green Cross Corp:The Water-soluble cholesterol derivative
US4639420A (en) * 1984-11-21 1987-01-27 Schaffner Carl P Method for the immunoanalysis of cholesterol epoxides
US4917998A (en) * 1986-05-06 1990-04-17 Epitope, Inc. Method of detecting AIDS virus infection
IT1212141B (it) * 1987-06-03 1989-11-08 So Ri Far S R L Composizioni farmaceutiche per la prevenzione e terapia della calcolosi delle vie biliari e della dispepsia biliare.
WO1989003212A1 (en) * 1987-10-13 1989-04-20 Pfizer Inc. 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5506223A (en) * 1990-08-29 1996-04-09 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
JPH0749438B2 (ja) 1990-10-31 1995-05-31 東京田辺製薬株式会社 タウリン抱合型胆汁酸の精製方法
IL105050A0 (en) 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
IT1255241B (it) 1992-07-22 1995-10-20 Simos Contos Derivato di acido biliare e suo uso in terapia
IT1255486B (it) * 1992-08-04 1995-11-06 Erregierre Ind Chim Processo per preparare gli acidi biliari coniugati con la taurina
US5482935A (en) * 1993-01-05 1996-01-09 American Home Product Corporation Anti-atherosclerotic use of 17 alpha-dihydroequilin
TW289757B (enExample) * 1993-05-08 1996-11-01 Hoechst Ag
IT1270853B (it) * 1993-05-20 1997-05-13 Sanofi Elf Procedimento per la preparazione di derivati taurocolanici
CN1055929C (zh) 1993-09-20 2000-08-30 中国科学院上海有机化学研究所 三氟甲基甾体化合物及其制备方法
IT1274000B (it) * 1994-04-06 1997-07-14 Alfa Wassermann Spa Derivati di acidi biliari utili nella terapia della calcolosi biliare da colesterolo e nelle patologie indotte da colestasi
KR970703359A (ko) * 1994-05-19 1997-07-03 위노쿠르 멜빈 알릴 그룹을 갖는 스테로이드의 산화(Oxidation of steroids having allylic groups)
US5583239A (en) * 1995-05-30 1996-12-10 Lehigh University Antimicrobial sterol conjugates
AU5928898A (en) 1997-01-24 1998-08-18 Regents Of The University Of California, The Use of fxr, pparalpha and lxralpha activators to restore barrier function, promote epidermal differentiation and inhibit proliferation
US6060465A (en) * 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
US7012069B2 (en) * 2001-05-03 2006-03-14 Arch Development Corporation Liver X receptor agonists
ES2326850T3 (es) * 1998-12-23 2009-10-20 Glaxo Group Limited Ensayos para ligandos de receptores nucleares.
AU2409600A (en) * 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
BR0010197A (pt) 1999-04-30 2002-07-16 Arch Dev Corp Derivados de esteróides
JP2002030096A (ja) 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd 神経細胞突起再生剤及びその製造方法
JP2002030097A (ja) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd ステロイド誘導体の製造方法
DE10105041A1 (de) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
EP1385868A4 (en) 2001-02-08 2004-12-08 Univ Chicago STEROID DERIVATIVE
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
CA2466033A1 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
CA2482195A1 (en) * 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers

Similar Documents

Publication Publication Date Title
JP2013508279A5 (enExample)
JP2015505296A5 (enExample)
JP2013537203A5 (enExample)
TWI598098B (zh) 脂質異常症治療劑
JP2012525393A5 (enExample)
RU2016103139A (ru) Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
JP2013512277A5 (enExample)
JP2013518107A5 (enExample)
JP2010521516A5 (enExample)
JP2009507909A5 (enExample)
JP2013079282A5 (enExample)
JP2009084270A5 (enExample)
JP2011504903A5 (enExample)
JP2020507589A5 (enExample)
JP2015508092A5 (enExample)
JP2008533007A5 (enExample)
JP2014505107A5 (enExample)
JP2009500423A5 (enExample)
JP2011046708A5 (enExample)
JP2015521156A5 (enExample)
JP2013506674A5 (enExample)
JP2016512227A5 (enExample)
RU2007102576A (ru) Новые индаэолкарбоксамиды и их применение
RU2012137245A (ru) Индуктор считывания и терапевтический агент для генетических заболеваний, вызванных мутациями типа нонсенс-мутаций
JP2014511897A5 (enExample)